Press releases

* (R) = Regulatory press releases

Dec 30, 2020

(R) New number of shares and votes in Cantargia

Dec 21, 2020

(R) Changes to Cantargia’s nomination committee

Dec 16, 2020

(R) Cantargia has completed a directed share issue of approximately SEK 564 million

Dec 15, 2020

(R) Cantargia announces intention of a directed share issue

Nov 26, 2020

BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

Nov 12, 2020

(R) Cantargia publishes interim report for third quarter 2020

Oct 20, 2020

(R) Nomination Committee appointed ahead of 2021 Annual General Meeting

Oct 13, 2020

(R) Extraordinary general meeting in Cantargia AB (publ)

Oct 8, 2020

(R) Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy

Oct 2, 2020

(R) Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab

Sep 23, 2020

(R) Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps

Sep 21, 2020

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Sep 21, 2020

(R) Cantargia’s nomination committee proposes a new board member

Aug 20, 2020

(R) Cantargia publishes half year report

Jul 31, 2020

(R) New number of shares and votes in Cantargia

Jun 23, 2020

(R) Cantargia strengthens management team with VP Regulatory Affairs and VP CMC

Jun 22, 2020

(R) Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting

May 27, 2020

(R) Annual General Meeting in Cantargia AB (publ)

May 27, 2020

(R) Cantargia publishes interim report for first quarter 2020

May 15, 2020

(R) Cantargia presents new preclinical data on CAN04 in combination with chemotherapy at the 2020 AACR Annual Meeting

May 4, 2020

(R) Cantargia IND application for CAN04 approved by FDA

Apr 28, 2020

(R) Notice of annual general meeting in Cantargia AB (publ)

Apr 7, 2020

(R) Cantargia submits IND application for CAN04

Apr 7, 2020

(R) Cantargia provides update on development projects CAN04 and CAN10

Mar 31, 2020

(R) New number of shares and votes in Cantargia

Mar 20, 2020

(R) Prospectus relating to the listing of shares in Cantargia published

Mar 16, 2020

(R) Extraordinary general meeting in Cantargia AB (publ)

Mar 10, 2020

(R) Cantargia acquires Cellerant IP on IL1RAP

Feb 28, 2020

(R) New number of shares and votes in Cantargia

Feb 27, 2020

(R) Cantargia publishes full year report for 2019

Feb 25, 2020

(R) Cantargia appoints Dr. Ignacio Garcia-Ribas as Chief Medical Officer

Feb 20, 2020

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Feb 19, 2020

(R) Cantargia has completed a directed share issue of approximately SEK 410 million

Feb 19, 2020

(R) Cantargia announces intention of a directed share issue

Feb 14, 2020

(R) Cantargia advances development of CAN04 through successful production scale up

In media

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2024-12-10

Redeye

Interview with CEO VD Göran Forsberg (In Swedish) - 2024-12-10

BioStock

Redeye interviews CEO Göran Forsberg about the expansion of CAN10's phase 1 study (In Swedish) - 2024-12-02

Redeye

Interview with CEO Göran Forsberg about the expansion of CAN10's phase 1 study and rights issue (In Swedish) - 2024-12-02

Biostock

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer - 2024-10-14

Redeye

Interview with CEO Göran Forsberg about new results from the phase 1 study of CAN10 - 2024-08-12

Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer - 2024-06-28

Redeye

Interview with CEO Göran Forsberg about the new neuropathy results with nadunolimab in pancreatic cancer that will be presented at ASCO. (In Swedish) - 2024-05-24

Redeye

CEO Göran Forsberg interviewed on new results with CAN10 and external validation of IL-1 blockade during inflammatory disease. (In Swedish) - 2023-03-15

Redeye

Redeye interviews CEO Göran Forsberg about new results on nadunolimab and alleviation of neuropathy during chemotherapy. (In Swedish) - 2024-02-14

Redeye

COO Liselotte Larsson presents at Redeye Life Science Day - 2023-11-23

Redeye

CEO Göran Forsberg comments on the quarterly report (In Swedish) - 2023-11-10

Di TV

Interview with CEO Göran Forsberg about the directed share issue (In Swedish) - 2023-10-31

Redeye

Interview with CEO Göran Forsberg about new TRIFOUR results (In Swedish) - 2023-10-23

Redeye

CEO Interview, New results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AARC (In Swedish) - 2023-10-02

Redeye

CEO Interview, about expanded clinical pipeline and start of treatment in CAN10, for autoimmune diseases. (In Swedish) - 2023-09-05

Redeye

CEO interview, about the new readout from trials in non-small cell lung cancer - 2023-05-31

Redeye

CEO interview, Interim efficacy results nadunolimab (In Swedish) - 2023-05-31

Västra Hamnen Corporate Finance

CEO interview, Promising interim efficacy results for nadunolimab in lung cancer - 2023-05-26

Di TV

Cantargia presents updated interim results - 2023-05-26

Di TV

CEO interview, New clinical development strategy for nadunolimab in pancreatic cancer - 2023-05-17

Redeye

CEO interview, Positive results published at the AARC-conference 2023 - 2023-04-19

Redeye

CEO interview, New positive research results (In Swedish) - 2023-03-15

DiTV

CEO interview, CANFOUR new Biomarker data (In Swedish)- 2023-03-15

Redeye

CEO interview, TRIFOUR result (In Swedish)- 2023-02-23

Redeye

CEO interview, Redeye Life Science Day (In Swedish) - 2022-11-24

Redeye

CEO interview, Edison - 2022-06-24

Edison

CEO interview, Rights issue, Redeye (In Swedish) - 2022-06-22

Redeye

CEO interview, Edison - 2022-03-16

Edison

Panel discussion – Business development

Redeye

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

Di

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv